Aprepitant Capsules Exporter from India | Genliva Wellness LLP Pharma Manufacturer

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Genliva Wellness LLP is a trusted Aprepitant Capsules Manufacturer in India producing advanced antiemetic formulations for oncology supportive care and cancer treatment management.

Aprepitant Capsules are widely prescribed for the prevention of chemotherapy-induced nausea and vomiting (CINV), particularly delayed emesis associated with highly emetogenic and moderately emetogenic chemotherapy regimens. The formulation contains Aprepitant, a neurokinin-1 (NK1) receptor antagonist that helps block substance P activity involved in nausea and vomiting pathways.

The company also supplies these formulations as an Oncology Supportive Care Medicine Supplier and Antiemetic Capsules Exporter for cancer care centers, hospital oncology departments, institutional procurement programs, and regulated international pharmaceutical markets.

Aprepitant Capsules are formulated for chemotherapy-induced nausea and vomiting prevention.

Contains Aprepitant as active ingredient
NK1 receptor antagonist formulation
Oral antiemetic capsule dosage form
Designed for delayed emesis prevention
Used in combination antiemetic therapy
Suitable for oncology supportive care

This formulation is prescribed in antiemetic and oncology supportive care management.

Prevention of chemotherapy-induced nausea
Prevention of chemotherapy-induced vomiting
Management of delayed emesis episodes
Used in highly emetogenic chemotherapy regimens
Used in moderately emetogenic chemotherapy regimens
Supports cancer treatment tolerance

Aprepitant Capsules deliver targeted antiemetic support during cancer treatment.

Helps reduce delayed nausea episodes
Supports prevention of chemotherapy-related vomiting
NK1 receptor targeted mechanism of action
Convenient oral capsule administration
Useful in combination antiemetic protocols
Enhances patient comfort during chemotherapy treatment